Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes [0.03%]
UGN-101治疗上尿路尿路上皮癌的早期经验 - 对实践模式和结果的多中心评估
Solomon L Woldu,Craig Labbate,Katie S Murray et al.
Solomon L Woldu et al.
Background: UGN-101 is a novel delivery system for intracavitary treatment of upper tract urothelial cancer (UTUC). UGN-101 was approved based on a pivotal trial for small volume residual low-grade UTUC. Our aim was to re...
Multicenter Study
Urologic oncology. 2023 Mar;41(3):147.e15-147.e21. DOI:10.1016/j.urolonc.2022.10.029 2023
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis [0.03%]
转移性激素敏感型前列腺癌三联疗法的出现：最新系统评价与网络荟萃分析
Niranjan J Sathianathen,Henry Y C Pan,Nathan Lawrentschuk et al.
Niranjan J Sathianathen et al.
Introduction: There have been a growing number of treatment options available for men with metastatic castration-sensitive prostate cancer. Not only have newer agents entered the clinical landscape, there is a trend towar...
Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship [0.03%]
根治性膀胱癌手术后膀胱癌患者继发原发恶性肿瘤的竞争死亡风险：对生存的影响
Patrick J Hensley,Zhigang Duan,Kelly Bree et al.
Patrick J Hensley et al.
Introduction: Muscle-invasive bladder cancer (BC) often occurs in patients with competing mortality risks, while also being associated with the highest rate of second primary nonurothelial cancers (SNUC) of all solid mali...
Implementation of a comprehensive prehabilitation program for patients undergoing radical cystectomy [0.03%]
全面实施根治性膀胱切除术患者的康复计划
Woodson W Smelser,Jacob E Tallman,Veerain K Gupta et al.
Woodson W Smelser et al.
Background: Coordinated preoperative optimization programs for radical cystectomy (RC) are limited and non-comprehensive. We evaluated the feasibility and acceptability of a coordinated, multi-faceted prehabilitation prog...
Radical prostatectomy readmissions: Causes, risk factors, national rates, & costs [0.03%]
根治性前列腺切除术再次入院：原因、风险因素、全国比率和费用
Shiva Balasubramanian,Xi Wang,An-Lin Cheng et al.
Shiva Balasubramanian et al.
Introduction: Readmissions have substantial clinical and financial impacts on the healthcare system. Radical prostatectomy (RP) is considered a standard treatment in the management of clinically localized prostate cancer....
Bladder cancer is associated with decreased urinary microbiota diversity and alterations in microbial community composition [0.03%]
膀胱癌与尿微生物群多样性降低以及微生物群组成改变有关
Jan Hrbáček,Vojtěch Tláskal,Pavel Čermák et al.
Jan Hrbáček et al.
Introduction: Human urine microbiota (UM) research has uncovered associations between composition of microbial communities of the lower urinary tract and various disease states including several reports on the putative li...
Chromosome 8q arm overexpression is associated with worse prostate cancer prognosis [0.03%]
染色体8q臂过表达与前列腺癌预后较差相关
Mohammed Alshalalfa,Tiffany T Nguyen,Konrad H Stopsack et al.
Mohammed Alshalalfa et al.
Objective: Chromosome 8q arm (chr8q) is the most amplified chromosomal segment in advanced metastatic castration-resistant prostate cancer after chXq12. These regions harbor important oncogenes driving prostate cancer pro...
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer [0.03%]
导电热化化疗与卡介苗C电磁给药作为伴有中度或高度危险非肌肉侵入性膀胱癌患者的腔内辅助治疗的对比研究
María Teresa Melgarejo Segura,Ana Morales Martínez,Yaiza Yáñez Castillo et al.
María Teresa Melgarejo Segura et al.
Background: Devices that increase the penetration of intravesical chemotherapeutic agents have been developed as alternatives to the use of bacillus Calmette-Guérin, in short supply at a time of increasing global inciden...
Observational Study
Urologic oncology. 2023 Feb;41(2):109.e1-109.e8. DOI:10.1016/j.urolonc.2022.10.019 2023
Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer [0.03%]
在恩杂鲁胺治疗前及治疗期间低睾酮浓度对转移性去势抵前列腺癌的预测价值
Lennart J van Winden,Mirthe Lanfermeijer,Vincent Dezentje et al.
Lennart J van Winden et al.
Background: Enzalutamide is an effective treatment for metastatic castration-resistant prostate cancer (mCRPC) patients. However, variances in responses are observed and there is a need for biomarkers predicting treatment...
Masaki Shiota,Satoshi Endo,Leandro Blas et al.
Masaki Shiota et al.
Castration resistance is in part attributable to aberrant activation of androgen receptor (AR) signaling by the intracrine activation of androgen precursors derived from adrenal glands. To overcome this, novel AR pathway inhibitors (ARPIs) ...